Literature DB >> 12642292

Behçet's syndrome.

M R Stanford.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12642292      PMCID: PMC1771611          DOI: 10.1136/bjo.87.4.381

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  6 in total

1.  Treatment of recalcitrant orogenital ulceration of Behçet's syndrome with infliximab.

Authors:  L P Robertson; P Hickling
Journal:  Rheumatology (Oxford)       Date:  2001-04       Impact factor: 7.580

2.  Role of gamma delta T cells in pathogenesis and diagnosis of Behcet's disease.

Authors:  A Hasan; F Fortune; A Wilson; K Warr; T Shinnick; Y Mizushima; R van der Zee; M R Stanford; J Sanderson; T Lehner
Journal:  Lancet       Date:  1996-03-23       Impact factor: 79.321

3.  Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

Authors:  P P Sfikakis; P G Theodossiadis; C G Katsiari; P Kaklamanis; N N Markomichelakis
Journal:  Lancet       Date:  2001-07-28       Impact factor: 79.321

4.  Behçet's disease in Japan and in Great Britain: a comparative study.

Authors:  M Muhaya; S Lightman; E Ikeda; M Mochizuki; B Shaer; P McCluskey; H M Towler
Journal:  Ocul Immunol Inflamm       Date:  2000-09       Impact factor: 3.070

5.  Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study.

Authors:  Erkan Alpsoy; Cicek Durusoy; Ertan Yilmaz; Yilmaz Ozgurel; Oya Ermis; Sahin Yazar; Erdal Basaran
Journal:  Arch Dermatol       Date:  2002-04

6.  Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody.

Authors:  S P Travis; M Czajkowski; D P McGovern; R G Watson; A L Bell
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

  6 in total
  1 in total

1.  Alpha tropomyosin as a self-antigen in patients with Behçet's disease.

Authors:  S P Mahesh; Zhuqing Li; R Buggage; F Mor; I R Cohen; E Y Chew; R B Nussenblatt
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.